Sonnet BioTherapeutics Holdings, Inc.
Price Action
Technical Summary
EMERGING TRENDSonnet BioTherapeutics Holdings, Inc. shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is weak (RS Rating: 4), showing significant lag compared to the market leaders. Earnings growth of 83% provides fundamental context to the price action. Investors should exercise caution due to high volatility (244% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $4.25 | -70.35% | BELOW |
| 50 SMA | $4.52 | -72.14% | BELOW |
| 100 SMA | $4.40 | -71.39% | BELOW |
| 150 SMA | $3.56 | -64.57% | BELOW |
| 200 SMA | $3.01 | -58.15% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is SONN in an uptrend right now?
SONN has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is SONN overbought or oversold?
SONN's RSI (14) is 28. The stock is oversold (RSI < 30), which could indicate a bounce opportunity.
Is SONN outperforming the market?
SONN has a Relative Strength (RS) Rating of 4 out of 99. SONN is currently lagging the broader market.
Where is SONN in its 52-week range?
SONN is trading at $1.26, which is 7% of its 52-week high ($19.30) and 1% above its 52-week low ($1.11).
How volatile is SONN?
SONN has a Beta of 2.78 and 52-week volatility of 244%. It's more volatile than the S&P 500 - expect bigger swings.